Biogen, Inc. (BIIB)
$300.51 3.96 (1.30%)
18:39 EDT BIIB Stock Quote Delayed 20 Minutes
Previous Close $300.51
Market Cap 63.41B
PE Ratio 21.47
Volume (Avg. Vol.) 1.42M
Day's Range 296.81 - 311.53
52-Week Range 215.77 - 374.99
Dividend & Yield N/A (N/A)
BIIB Stock Predictions, Articles, and Biogen, Inc. News
- From InvestorPlace
- From the Web
Tuesday's big stock charts feature stocks holding support whose businesses could, and maybe should, hold up in the near term.
By Ian Cooper
One of the best ways to profit is to invest like Warren Buffett. Here are three Berkshire Hathaway stocks that he's watching now.
Ford and Disney sank on earnings, while oil demand could shrivel up in China. Here's what happened in the stock market today.
The only thing more important than what to buy is what not to buy. These biotech stocks are at the top of the avoid list. Here's why.
Wednesday's big stock charts highlight 3 stocks looking to break through resistance in a market that looks a bit shaky at the moment.
Value stocks are hot these days, and the best part is the shift toward them isn't stopping anytime soon. Here are five to buy today.
With biotech stocks back in favor, investors may selectively pick only those with a deep drug pipeline ahead.
This morning, I'm recommending a bullish call option on Aimmune Therapeutics, Inc. (NASDAQ:AIMT), the biopharmaceutical company.
Options trading was buzzing in Biogen, McDonald's and Lyft stock on Tuesday. Here are the metrics that matter moving forward.
Biogen erupted in early trading, as it seeks approval for its Alzheimer's treatment. Here's what happened in the stock market today.
Another opioid settlement has been reached and earnings season is heating up. Here's what happened in the stock market today.
When rumors start buzzing that the government may be about to intervene, then biotech stocks often get slammed...some fairly, and some not (as we’ll see).
Biogen earnings for the second quarter of the year have BIIB stock heading higher on Tuesday thanks to a strong EPS and revenue beat.
The owners of Biogen stock will examine Biogen earnings to asss the progress that BIIB is making in key areas, including Ms and Spinraza.
Investors saw new highs in the Nasdaq today, but the index finished slightly lower on the day. Here's what we're watching now.
The second quarter is the books, at least as far as the stock market is concerned. Here's a look at the Nasdaq today.
From The Motley Fool
From The Motley Fool
Navellier RatingsPowered by Portfolio Grader